Skip to main content

Table 1 Patient’s characteristics

From: Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042

Patient # Subtype1 Stage at baseline Biopsies2
10 FCBCL NA Baseline, C1
13 CD30+ ALCL IIB Baseline, C1
16 CD30+ ALCL IIA Baseline, C1, C2
17 GSS IB Baseline, C1, C2, C3, C4, C6, C9, C10
18 MF IIB Baseline, C1, C2
20 CD30+ ALCL IIB Baseline, C1
24 Pleomorphic CTCL IB Baseline, C1, C4, Last Visit
25 MF IB Baseline, C1, C4, Last Visit
27 MF IIB Baseline, C1
29 MF IB Baseline, C1, Last Visit
30 MF IB Baseline, C1, C4
31 MF IIB Baseline, C1, C4
33 DLBCL T3a Baseline, C1
34 MF IB Baseline, C1, Last Visit
35 MZBCL T3b Baseline, C1
36 MF IB Baseline, C1, C4
37 CD30+ ALCL IIB Baseline, C2
38 MF IB Baseline, C1, C4, Last Visit
39 MF IIB Baseline, C1, C3
  1. Summary of relevant information for each patient analysed (patient number, histology subtype, stage at baseline and time of biopsies sampling).
  2. NA not applicable.
  3. 1Pathology subtypes: ALCL indicates anaplastic large cell lymphoma, MF Mycosis fungoides, CBCL cutaneous B-cell lymphoma, DLBCL diffuse large B-cell lymphoma, FCBCL follicle center B-cell lymphoma, MZBCL marginal zone B-cell lymphoma, Pleomorphic CTCL Pleomorphic cutaneous T-cell lymphoma, LyP lymphomatoid papulosis, GSS granulomatous slack skin.
  4. 2Cx: C:Cycle. x: cycle number at which the examined biopsies were sampled. See Material and Methods for Cycle definition.